Kerendia (finerenone) is an FDA-approved oral medication for adults with chronic kidney disease (CKD) associated with Type 2 diabetes. It belongs to a class of drugs called non-steroidal mineralocorticoid receptor antagonists (MRAs) and is the first in this class approved specifically to reduce the risk of kidney disease progression and cardiovascular events in people with diabetic CKD.
🫀 Diabetes & Kidney Protection: If you have Type 2 diabetes and chronic kidney disease, ask our endocrinologists about Kerendia and comprehensive kidney protection strategies. Call 832-968-7003.
Why Does Diabetic CKD Need Special Attention?
Diabetic kidney disease (diabetic nephropathy) is the leading cause of kidney failure in the US. In Type 2 diabetes, chronic activation of the mineralocorticoid receptor (MR) in the kidneys and heart contributes to:
- Kidney inflammation and fibrosis (scarring)
- Progressive loss of kidney function
- Increased risk of heart failure, heart attack, and cardiovascular death
Even with standard therapies (ACE inhibitors/ARBs, SGLT2 inhibitors), significant residual kidney and cardiovascular risk remains. Kerendia addresses this residual risk through a complementary mechanism.
How Does Kerendia Work?
Kerendia selectively blocks the mineralocorticoid receptor (MR) in the kidneys and heart. Unlike older steroidal MRAs (spironolactone, eplerenone), finerenone:
- Has higher selectivity for the MR — fewer hormonal side effects (gynecomastia is rare)
- Reduces kidney inflammation and fibrosis
- Lowers proteinuria (protein in the urine — a marker of kidney damage)
- Reduces cardiovascular inflammation and stress on the heart
Clinical Evidence — The FIDELIO-DKD and FIGARO-DKD Trials
Kerendia was studied in two large Phase 3 trials involving over 13,000 patients with T2D and CKD:
- FIDELIO-DKD: 18% reduction in the risk of kidney failure, doubling of serum creatinine, or kidney death. Also reduced cardiovascular events.
- FIGARO-DKD: Significant reduction in cardiovascular death and non-fatal heart attacks; also reduced kidney disease progression
- Both trials were conducted on top of background ACE inhibitor or ARB therapy, demonstrating additive benefit
Who Should Take Kerendia?
Kerendia is indicated for adults with:
- Type 2 diabetes AND
- Chronic kidney disease (moderately to severely reduced kidney function or significant proteinuria)
- Already on maximum tolerated ACE inhibitor or ARB therapy
It is not approved for Type 1 diabetes or non-diabetic CKD. It is contraindicated in patients with Addison's disease or those taking strong CYP3A4 inhibitors (certain antifungals, antibiotics).
Key Side Effects to Monitor
- Hyperkalemia (high potassium) — the most important side effect. Potassium levels must be checked before starting and monitored regularly. Kerendia should not be initiated if potassium is above 5.0 mEq/L.
- Mild decrease in kidney function at initiation (expected; like ACE inhibitors)
- Hypotension (low blood pressure)
Because of the hyperkalemia risk, dietary potassium awareness and regular lab monitoring are essential during Kerendia therapy.
Kerendia in the Modern Diabetes Treatment Landscape
Current guidelines now recommend a comprehensive approach to kidney and heart protection in T2D:
| Drug Class | Key Benefit |
|---|---|
| ACE inhibitor / ARB | Reduce proteinuria, slow CKD progression |
| SGLT2 inhibitor (e.g., jardiance, farxiga) | Reduce kidney failure, heart failure, CV events |
| Kerendia (finerenone) | Reduce kidney inflammation/fibrosis, CV events — complementary to SGLT2i |
| GLP-1 agonist | Glucose control, weight, CV and kidney benefits |
Used together, these therapies provide comprehensive "cardiorenal protection" that no single agent achieves alone.
Key Takeaways
- Kerendia is the first non-steroidal MRA approved to slow diabetic CKD progression and reduce CV events
- Reduces kidney inflammation and fibrosis through a complementary mechanism to SGLT2 inhibitors and ACE inhibitors/ARBs
- Potassium monitoring is essential — hyperkalemia is the key side effect
- Used in T2D patients with CKD already on maximum ACE inhibitor/ARB therapy
- Part of modern comprehensive cardiorenal protection for diabetic kidney disease
Our Team Can Help with Your Medications
All five of our providers prescribe and manage endocrine medications. Book with any member of our team:
Book an Appointment → or call 832-968-7003